Esperion Th (ESPR)

NASDAQ
6.70
-0.26(-3.74%)
After Hours
6.67
-0.03(-0.45%)
- Real-time Data
  • Volume:
    624,613
  • Day's Range:
    6.57 - 6.91
  • 52 wk Range:
    3.28 - 13.14

ESPR Overview

Prev. Close
6.96
Day's Range
6.57-6.91
Revenue
89.31M
Open
6.84
52 wk Range
3.28-13.14
EPS
-5.49
Volume
624,613
Market Cap
445.9M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
996,537
P/E Ratio
-1.37
Beta
0.165
1-Year Change
-42.14%
Shares Outstanding
66,551,580
Next Earnings Date
Nov 08, 2022
What is your sentiment on Esperion Th?
or
Market is currently closed. Voting is open during market hours.

Esperion Th News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Esperion Th Analysis

Esperion Th Company Profile

Esperion Th Company Profile

Employees
0

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Read More

Analyst Price Target

Average10.80 (+61.19% Upside)
High22
Low3
Price6.7
No. of Analysts10
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellSellSell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryStrong BuyBuyStrong SellStrong SellStrong Sell
  • still waiting for 40$ is it possible this year?
    3
    • I think 20$ is hardly possible this year.
      1
  • So far, everything points to the fact that bempedoic acid is much safer than statins, and if we exclude the financial interest of large pharmaceutical companies in promoting their statins, then we should start with the appointment of bempedoic acid and only then strengthen its effect with statins if the effect is insufficient.
    0
    • Does anyone look at even the financials? This company is a dumpster fire, and the dumpster is full of cash and debt.
      0
      • Pre Market prise, what happened?
        1
        • $ 10.17 seems to me a good opportunity for range-bounds traders.
          2
          • 3RD Most Shorted Stock.
            0
            • They waited for 20 million in profit, but it turned out 8 only. CEO quietly mentioned that there are 30 million (!!!) not taken into this report. 2 payments were not included in the report from Daiichi and Oberland capital (30 mln)
              0
              • I think ESPR has a lot of potential. Also a chance of a nice short squeeze.  https://www.moneyshow.com/articles/tptp2021-55871/
                0
                • ESPR is heavily shorted. seems there will be short squeeze just like #GMO and #AMC
                  0
                  • Buy opportunity
                    0
                    • great keep going up
                      0